TUCSON, Ariz., July 19, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that it will host a key opinion leader (KOL) webinar on “Drug Candidate Attrition – How to Improve Clinical Development Success and Patient Outcomes” on Wednesday, July 27, 2022 at 10:00 am Eastern Time.
HTG Molecular Diagnostics Hosting a KOL Event Addressing Drug Candidate Attrition
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here